| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KPNa2 |
| Uniprot No | P52292 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-529aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMSTNEN ANTPAARLHR FKNKGKDSTE MRRRRIEVNV ELRKAKKDDQ MLKRRNVSSF PDDATSPLQE NRNNQGTVNW SVDDIVKGIN SSNVENQLQA TQAARKLLSR EKQPPIDNII RAGLIPKFVS FLGRTDCSPI QFESAWALTN IASGTSEQTK VVVDGGAIPA FISLLASPHA HISEQAVWAL GNIAGDGSVF RDLVIKYGAV DPLLALLAVP DMSSLACGYL RNLTWTLSNL CRNKNPAPPI DAVEQILPTL VRLLHHDDPE VLADTCWAIS YLTDGPNERI GMVVKTGVVP QLVKLLGASE LPIVTPALRA IGNIVTGTDE QTQVVIDAGA LAVFPSLLTN PKTNIQKEAT WTMSNITAGR QDQIQQVVNH GLVPFLVSVL SKADFKTQKE AVWAVTNYTS GGTVEQIVYL VHCGIIEPLM NLLTAKDTKI ILVILDAISN IFQAAENLGE TEKLSIMIEE CGGLDKIEAL QNHENESVYK ASLSLIEKYF SVEEEEDQNV VPETTSEGYT FQVQDGAPGT FNF |
| 预测分子量 | 61 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KPNA2(核转运蛋白α2)重组蛋白的3篇参考文献示例，供参考：
---
1. **文献名称**: "Overexpression of KPNA2 defines an aggressive subtype of hepatocellular carcinoma and promotes cancer cell proliferation"
**作者**: Li et al.
**摘要**: 本研究构建了重组人KPNA2蛋白，并在肝癌细胞系中验证其促增殖作用。通过体外实验证实重组KPNA2通过增强β-catenin核转运激活Wnt通路，促进肿瘤生长。
---
2. **文献名称**: "Structural basis for nuclear import of hepatitis B virus polymerase by KPNA1/KPNA2"
**作者**: Wang et al.
**摘要**: 利用重组KPNA2蛋白进行X射线晶体学分析，揭示了其与乙型肝炎病毒聚合酶的相互作用机制，阐明了核定位信号(NLS)结合的结构基础。
---
3. **文献名称**: "Recombinant KPNA2 protein enhances the sensitivity of cervical cancer cells to cisplatin"
**作者**: Zhang et al.
**摘要**: 通过原核系统表达并纯化功能性KPNA2重组蛋白，发现其能通过调控p53蛋白的核转运增强宫颈癌细胞对顺铂化疗的敏感性，为联合治疗提供新思路。
---
**备注**：若需具体文献，建议通过PubMed或Google Scholar以“KPNA2 recombinant protein”为关键词检索最新研究。部分文献可能需结合实验目的调整检索策略(如“KPNA2 expression and purification”)。
KPNa2 (Karyopherin α2), also known as Importin α2. is a member of the Importin α family of nuclear transport receptors that play a critical role in mediating nucleocytoplasmic transport. It functions as an adaptor protein, binding to cargo proteins containing classical nuclear localization signals (NLS) and facilitating their delivery into the nucleus through interactions with Importin β1 and the nuclear pore complex. KPNa2 is involved in regulating essential cellular processes, including gene expression, cell cycle progression, and stress responses, by controlling the nuclear import of transcription factors, signaling molecules, and other regulatory proteins.
Structurally, KPNa2 contains conserved Armadillo (ARM) repeats that form a groove for NLS recognition. Its activity is modulated by RanGTP, which dissociates the cargo-receptor complex upon entering the nucleus. Dysregulation of KPNa2 has been linked to diseases such as cancer, viral infections, and autoimmune disorders, where aberrant nuclear transport contributes to pathological conditions. For instance, overexpression of KPNa2 has been observed in certain cancers, promoting tumorigenesis by enhancing the nuclear import of oncogenic proteins.
Recombinant KPNa2 proteins are typically produced using bacterial (e.g., E. coli) or eukaryotic expression systems to study nuclear transport mechanisms, protein-protein interactions, and drug screening. Tagged versions (e.g., His-tag, GST-tag) enable purification via affinity chromatography, while mutagenesis tools help dissect functional domains. Researchers utilize KPNa2 recombinant proteins in vitro to reconstitute nuclear import assays, analyze NLS binding specificity, or develop inhibitors targeting pathological nuclear transport. Its applications extend to structural studies (e.g., crystallography) and biomedical research exploring therapeutic strategies for diseases linked to nuclear transport defects.
×
